Advanced search
Publication Cover
Scandinavian Journal of Urology Volume 51, 2017 - Issue 6
Journal homepage
240
Views
9
CrossRef citations to date
0
Altmetric
Original Article

Associations between statin use and progression in men with prostate cancer treated with primary androgen deprivation therapy

Marta Kramer MikkelsenDepartment of Urology, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0003-2081-5293View further author information
ORCID Icon,
Frederik Birkebæk ThomsenCopenhagen Prostate Cancer Center, Department of Urology, Rigshospitalet, University of Copenhagen, Copenhagen N, Denmark; View further author information
,
Kasper Drimer BergCopenhagen Prostate Cancer Center, Department of Urology, Rigshospitalet, University of Copenhagen, Copenhagen N, Denmark; View further author information
,
Mary JardenUniversity Hospitals Center for Health Research, Rigshospitalet, University of Copenhagen, Copenhagen Ø, Denmark; ORCID Iconhttp://orcid.org/0000-0003-3040-8384View further author information
ORCID Icon,
Signe Benzon LarsenCopenhagen Prostate Cancer Center, Department of Urology, Rigshospitalet, University of Copenhagen, Copenhagen N, Denmark; ;Danish Cancer Society Research Center, Copenhagen Ø, DenmarkORCID Iconhttp://orcid.org/0000-0001-9522-7678View further author information
ORCID Icon,
Rikke Bølling HansenDepartment of Urology, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; View further author information
&
Klaus BrassoCopenhagen Prostate Cancer Center, Department of Urology, Rigshospitalet, University of Copenhagen, Copenhagen N, Denmark; View further author information
 show all
Pages 464-469 | Received 15 Mar 2017, Accepted 19 Jul 2017, Published online: 23 Aug 2017

References

  • Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–1681.
  • Murtola TJ, Visakorpi T, Lahtela J, et al. Statins and prostate cancer prevention: where we are now, and future direction. Nat Clin Pract Urol. 2008;5:376–387.
  • Weis M, Heeschen C, Glassford AJ, et al. Statins have biphasic effects on angiogenesis. Circulation. 2002;105:739–745.
  • Park C, Lee I, Kang WK. Lovastatin-induced E2F-1 modulation and its effect on prostate cancer cell death. Carcinogenesis. 2001;22:1727–1731.
  • Toepfer N, Childress C, Parikh A, et al. Atorvastatin induces autophagy in prostate cancer PC3 cells through activation of LC3 transcription. Cancer Biol Ther. 2011;12:691–699.
  • Raval AD, Thakker D, Negi H, et al. Association between statins and clinical outcomes among men with prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2016;19:151–162.
  • Luo Y, She DL, Xiong H, et al. The prognostic effect of statin use on urologic cancers: an updated meta-analysis of 35 observational studies. Medicine (Baltimore). 2015;94:e1523.
  • Tan P, Wei S, Yang L, et al. The effect of statins on prostate cancer recurrence and mortality after definitive therapy: a systematic review and meta-analysis. Sci Rep. 2016;6:29106.
  • Sun LM, Lin MC, Lin CL, et al. Statin use reduces prostate cancer all-cause mortality: a nationwide population-based cohort study. Medicine (Baltimore). 2015;94:e1644.
  • Yu O, Eberg M, Benayoun S, et al. Use of statins and the risk of death in patients with prostate cancer. JCO. 2014;32:5–11.
  • Harshman LC, Wang X, Nakabayashi M, et al. Statin use at the time of initiation of androgen deprivation therapy and time to progression in patients with hormone-sensitive prostate cancer. JAMA Oncol. 2015;1:495–504.
  • Jung J, Lee C, Lee C, et al. Effects of statin use on the response duration to androgen deprivation therapy in metastatic prostate cancer. Korean J Urol. 2015;56:630–636.
  • Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383.
  • Mottet N, Bellmunt J, Briers E, et al. Guidelines on prostate cancer [Internet]. European Association of Urology; 2015 [cited 28 October 2016]. Available from: https://uroweb.org/wp-content/uploads/09-Prostate-Cancer_LR.pdf
  • Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17:343–346.
  • Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Statist. 1988;16:1141–1151.
  • Melvin JC, Garmo H, Daniel R, et al. An investigation into the relationship between statins and cancer using population-based data. BJU Int. 2015;116:681–683.
  • Stattin P, Loeb S. ‘To measure is to know. If you cannot measure it, you cannot improve it’: statistical modelling cannot compensate for unmeasured bias. Eur Urol. 2014;65:701–703.
  • Stattin P, Sandin F, Thomsen FB, et al. Association of radical local treatment with mortality in men with very high-risk prostate cancer: a semiecologic, Nationwide, Population-based Study. Eur Urol. 2017;72:125–134.
  • Hamilton RJ, Goldberg KC, Platz EA, et al. The influence of statin medications on prostate-specific antigen levels. J Natl Cancer Inst. 2008;100:1511–1518.
  • Mener DJ, Cambio A, Stoddard DG, et al. The impact of HMG-CoA reductase therapy on serum PSA. Prostate. 2010;70:608–615.
  • Marså K, Johnsen NF, Bidstrup PE, et al. Social inequality and incidence of and survival from male genital cancer in a population-based study in Denmark, 1994-2003. Eur J Cancer. 2008;44:2018–2029.
  • Larsen SB, Brasso K, Christensen J, et al. Socioeconomic position and mortality among patients with prostate cancer: influence of mediating factors. Acta Oncol. 2017;56:563–568.
  • Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013;(1):CD004816. doi: 10.1002/14651858.CD004816.pub5
  • Payne AH, Hales DB. Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocr Rev. 2004;25:947–970.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.